Clinical, molecular, and transplant-related variables in each MRD-defined group.
| Pretransplant MRD status . | High (n = 19) . | Low (n = 30) . | Negative (n = 58) . | P . |
|---|---|---|---|---|
| Median age, y | 53 | 53 | 54 | 1.0 |
| Range | 40-69 | 17-65 | 24-66 | |
| FLT3-ITD positive | 8 (42%) | 8 (27%) | 18 (31%) | .5 |
| FLT3-ITD allelic ratio > 0.5 | 4 (21%) | 3 (10%) | 7 (12%) | .4 |
| PB Post #2 MRD positive | 6/17 (35%) | 11/26 (42%) | 4/53 (8%) | .002 |
| Transplanted in CR1 | 5 (26%) | 20 (67%) | 31 (53%) | .16 |
| Myeloablative conditioning | 8 (42%) | 6 (20%) | 17 (29%) | .5 |
| Sibling donor | 6 (32%) | 14 (47%) | 23 (40%) | .7 |
| T-cell depletion | 16 (84%) | 25 (83%) | 41 (71%) | .15 |
| Pretransplant MRD status . | High (n = 19) . | Low (n = 30) . | Negative (n = 58) . | P . |
|---|---|---|---|---|
| Median age, y | 53 | 53 | 54 | 1.0 |
| Range | 40-69 | 17-65 | 24-66 | |
| FLT3-ITD positive | 8 (42%) | 8 (27%) | 18 (31%) | .5 |
| FLT3-ITD allelic ratio > 0.5 | 4 (21%) | 3 (10%) | 7 (12%) | .4 |
| PB Post #2 MRD positive | 6/17 (35%) | 11/26 (42%) | 4/53 (8%) | .002 |
| Transplanted in CR1 | 5 (26%) | 20 (67%) | 31 (53%) | .16 |
| Myeloablative conditioning | 8 (42%) | 6 (20%) | 17 (29%) | .5 |
| Sibling donor | 6 (32%) | 14 (47%) | 23 (40%) | .7 |
| T-cell depletion | 16 (84%) | 25 (83%) | 41 (71%) | .15 |
Spearman correlation P value is provided for the age comparison and Mantel-Haenszel P value is provided for all other variables.